| SEC | Form | 4 |
|-----|------|---|
|     |      |   |

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

|   |   | Table I Non I | Derivative Securities Acquired Dispessed of or Bone   | ficially Owned   |
|---|---|---------------|---|--|
| (City)  | (State)   | (Zip)         |   |  |
| DUBLIN 2  | L2  |               |   |  |
| (Street)  |   |               |   | Form filed by More than One Reporting Person   |
| FITZWILLIAM COURT, FL. 1, LEESON CLOSE                        |   |               | 4. Il Amendment, Date of Original Filed (Nonthibbay) Fear)                                    | X Form filed by One Reporting Person   |
| C/O ITERUM  | THERAPEUTIC   | S PLC         | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                      | 6. Individual or Joint/Group Filing (Check Applicable Line)  |
| (Last)  | (First)   | (Middle)      | 3. Date of Earliest Transaction (Month/Day/Year) 08/06/2024                                   | Officer (give title Other (specify below) below)   |
| 1. Name and Address of Reporting Person *<br>Dunne Michael W. |   |               | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Iterum Therapeutics plc</u> [ ITRM ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner |
|   | ended to satisfy the<br>nse conditions of Rule<br>Instruction 10. |               |   |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | te, Transaction<br>Code (Instr. |       | 4. Securities Ac<br>Disposed Of (D |   |            | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | Form: Direct (D) | Beneficial<br>Ownership |
|---------------------------------|--|---|---------------------------------|-------|------------------------------------|---|------------|--|------------------|-------------------------|
|                                 | Code V Amount                              |   | (A) or<br>(D)                   | Price | Transaction(s)<br>(Instr. 3 and 4) |   | (Instr. 4) |  |                  |                         |
| Ordinary Shares                 | 08/06/2024                                 |   | М                               |       | 106,247                            | A | (1)        | 220,001  | D                |                         |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 4.<br>Transac<br>Code (Ir<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of (D)<br>(Instr. 3, 4 and 5) |         | e and 7. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                    | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) |                                  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |   |  |
|---|---|--|---------------------------------|---|---|---------|--|--------------------|---|----------------------------------|--|--|---|--|
|   |   |  | Code                            | v | (A)   | (D)     | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount or<br>Number of<br>Shares |  | Reported<br>Transaction(s)<br>(Instr. 4)                           |   |  |
| Subscription<br>Rights (right to<br>buy)            | \$0.61  | 08/06/2024                                 | М                               |   |   | 212,494 | 07/22/2024   | 08/06/2024         | Units   | (2)                              | \$0  | 0  | D |  |
| Warrants (right<br>to buy)                          | \$1.21  | 08/06/2024                                 | М                               |   | 106,247   |         | 08/09/2024   | 08/09/2025         | Ordinary<br>Shares                                  | 53,123                           | (1)  | 106,247  | D |  |
| Warrants (right<br>to buy)                          | \$1.21  | 08/06/2024                                 | М                               |   | 106,247   |         | 08/09/2024   | 08/09/2029         | Ordinary<br>Shares                                  | 106,247                          | (1)  | 106,247  | D |  |

Explanation of Responses:

1. The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of \$1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of \$1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of \$1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").

2. The Reporting Person validly exercised 212,494 subscription rights to acquire 106,247 units composed of (i) 106,247 ordinary shares, (ii) 106,247 1-year warrants and (iii) 106,247 5-year warrants.

| /s/ Michael W. D     | <u>unne</u>   |
|----------------------|---------------|
| ** Signature of Repo | orting Person |

08/12/2024 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.